Previous close | 39.82 |
Open | 40.67 |
Bid | 39.83 x 100 |
Ask | 46.06 x 100 |
Day's range | 39.79 - 40.74 |
52-week range | 29.85 - 45.00 |
Volume | |
Avg. volume | 1,002,227 |
Market cap | 5.071B |
Beta (5Y monthly) | 1.25 |
PE ratio (TTM) | 19.00 |
EPS (TTM) | 2.10 |
Earnings date | 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 51.11 |
Laughing Water Capital, an investment management company, released its first-quarter 2024 investor letter. A copy of the same can be downloaded here. In the first quarter, investment in the fund returned 8.4% after all fees and expenses compared to 10.6% and 5.2% returns for the SP500TR and R2000 during the quarter, respectively. In addition, you […]
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.